Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.

Cancer chemotherapy and pharmacology·2026
Same author

Hemipelvectomy for Clostridium septicum necrotizing soft tissue infection with extensive pelvic organ destruction: a case report.

International journal of emergency medicine·2026
Same author

Olanzapine Use and Vomiting Incidence in Chemotherapy-receiving Patients With Cervical Cancer: Multicenter Post Hoc Analysis.

In vivo (Athens, Greece)·2026
Same author

Comprehension of medication-related information translated from Japanese to Southeast Asian Languages using google translate.

Journal of pharmaceutical health care and sciences·2026
Same author

Genomic analysis of dental pulp mesenchymal stromal cells for therapeutic applications.

Regenerative therapy·2026
Same author

Evidence of megathrust earthquakes and seismic supercycles in subtropical Japan from millennia-old coral microatolls.

Nature communications·2026

Related Experiment Video

Updated: Mar 24, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

[Companion Diagnostics for Solid Tumors].

Atsushi Watanabe

    Rinsho Byori. the Japanese Journal of Clinical Pathology
    |March 22, 2016
    PubMed
    Summary

    Companion diagnostics (CoDx) are vital for personalized medicine, enabling targeted therapies in oncology. Developing CoDx requires collaboration to overcome challenges in business models and regulations.

    Area of Science:

    • Oncology
    • Pharmacogenomics
    • Molecular Diagnostics

    Background:

    • Companion diagnostics (CoDx) are increasingly used in solid tumors, guiding targeted therapies like EGFR inhibitors in lung cancer and HER2-targeted treatments in breast cancer.
    • CoDx are integral to personalized medicine and pharmacogenomics, linking specific genetic markers to drug efficacy.
    • Examples include EGFR for gefitinib, ALK for crizotinib, KRAS for cetuximab/panitumumab, and HER2 for trastuzumab.

    Purpose of the Study:

    • To review the growing role and applications of companion diagnostics in oncology.
    • To identify and discuss the challenges in companion diagnostic development, including business models and regulatory hurdles.
    • To highlight the importance of collaboration among stakeholders for successful CoDx implementation.

    Main Methods:

    More Related Videos

    Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
    06:53

    Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

    Published on: June 8, 2019

    9.3K
    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
    10:35

    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

    Published on: April 5, 2018

    10.9K

    Related Experiment Videos

    Last Updated: Mar 24, 2026

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    25.2K
    Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
    06:53

    Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

    Published on: June 8, 2019

    9.3K
    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
    10:35

    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

    Published on: April 5, 2018

    10.9K
    • Literature review of companion diagnostic applications and development trends.
    • Analysis of regulatory recommendations and industry best practices.
    • Discussion of technological advancements impacting CoDx, such as next-generation sequencing and multiplex diagnostics.

    Main Results:

    • Companion diagnostics are essential for precision medicine, with expanding applications in various cancers.
    • Significant challenges persist in CoDx development, particularly concerning industry collaboration and regulatory frameworks.
    • Advances in genomic technologies facilitate multiplex diagnosis for identifying germline and somatic mutations.

    Conclusions:

    • The development of companion diagnostics necessitates close collaboration between academic institutions, regulatory bodies, and pharmaceutical companies.
    • Addressing business model and regulatory challenges is crucial for the continued growth and effective implementation of CoDx.
    • Technological progress supports the expanding utility of CoDx in precision cancer care.